ABVX.PA ABIVAX | FR0012333284
Company Profile
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Latest News
Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565
PR Newswire • 07/27/2026
UK TV comedy star and naturalist Bill Oddie dies at 85
AFP • 07/27/2026
German creator of 'Body Worlds' anatomy exhibits dead at 81
AFP • 07/27/2026
Prediction Markets Are Booming, Crypto Markets Are Not. Here's What That Means for Crypto Investors
Motley Fool • 07/27/2026
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.abivax.com |
| Audit Risk | 9 |
| Board Risk | 10 |
| Overall Risk | 10 |
| Market Cap | 9.73B |
| Forward P/E | -42.22 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -4.61 |
| Forward EPS | -2.64 |
| Book Value | 5.42 |
| Price-to-Book | 20.6 |
| Enterprise-to-Revenue | 1,724.94 |
| Enterprise-to-EBITDA | -33.41 |
| Earnings Date | 09/21/2026 |
| Earnings Call Date | |
| Revenue Average | 819,070 |
| Revenue Low | 0 |
| Revenue High | 1.63M |